SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AQUILA BIOPHARMACEUTICALS INC (AQLA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tnsaf who wrote (28)4/27/2000 7:43:00 PM
From: AurumRabosa  Read Replies (1) of 45
 
I seriously doubt they needed insider information to make their investment decision. It appears to have been clear from earlier trials that Quilvax-M works. For example, this old article still makes for good reading:

Goodger says the product helps maintain the normal quality of the milk. Cows with mastitis tend to produce milk with a high somatic cell count, which are inflammatory white blood cells that greatly devalue the milk.

"In previous trials, we were able to show that the somatic cell counts of the animals stayed relatively normal," he says.

news.wisc.edu

Quilvax-M could be on the market this year. They have a lot of other products in the pipeline and I believe the CD1 technology could be huge. I'm researching journal articles on CD1 now and wondering if a leprosy vaccine is in the cards.
jimmunol.org
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News